Wells Fargo & Company Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target reduced by investment analysts at Wells Fargo & Company from $15.00 to $12.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 7.33% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Barrington Research reiterated an “outperform” rating and set a $18.00 price objective on shares of DENTSPLY SIRONA in a research report on Wednesday, October 29th. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Thursday. UBS Group dropped their price objective on shares of DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Evercore ISI cut their price objective on shares of DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating for the company in a report on Wednesday, October 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of DENTSPLY SIRONA in a research report on Friday, September 26th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, DENTSPLY SIRONA presently has a consensus rating of “Hold” and a consensus price target of $16.42.

DENTSPLY SIRONA Stock Up 1.5%

Shares of XRAY opened at $11.18 on Friday. The firm’s 50-day simple moving average is $12.98 and its 200 day simple moving average is $14.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69. The firm has a market cap of $2.23 billion, a P/E ratio of -2.36, a price-to-earnings-growth ratio of 0.81 and a beta of 1.00. DENTSPLY SIRONA has a 52 week low of $10.69 and a 52 week high of $20.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.08). The firm had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.33 million. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. DENTSPLY SIRONA’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. On average, analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brooklyn Investment Group acquired a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the 1st quarter valued at approximately $26,000. Trust Co. of Toledo NA OH acquired a new stake in DENTSPLY SIRONA in the second quarter valued at approximately $27,000. Parkside Financial Bank & Trust grew its stake in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 1,477 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 8,003.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 2,241 shares in the last quarter. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.